ADC Control Human IgG1-vcMMAE (DAR8) 

ADC Control Human IgG1-vcMMAE (DAR8) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575)^[1].

Antibody-drug conjugates (ADCs) covalently link a highly efficient small molecule toxin to an antibody through a suitable linker. For therapeutic antibody-drug conjugates (ADCs) in cancer treatment, the antibody targets a specific antigen on the surface of tumor cells with high binding affinity, and then the intact ADC is internalized by the tumor cells along with the antigen and digested in lysosomes to release the antitumor toxin [1].
VcMMAE (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells^[2].
MMAE sensitizes colorectal and pancreatic cancer cells to IR in a time- and dose-dependent manner associated with mitotic arrest. Radiosensitization is manifested as decreased clonogenic survival and increased DNA double-strand breaks in irradiated cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

[ADC Control Human IgG1-vcMMAE (DAR8)]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tushar D Nichakawade, et al. TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers. Nature. 2024 Apr;628(8007):416-423.  [Content Brief]

  [2]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.  [Content Brief]

  [3]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.  [Content Brief]